Menu
Recruiting NCT06302413

Enhancing Prospective Thinking in Early Recovery (HOME)

No phase Interventional Alcohol Use Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Virtual Reality, Virtual Reality.
Who it may be relevant to
Registry conditions: Alcohol Use Disorder. Basic parameters: 18 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Enhancing Prospective Thinking in Early Recovery

Overview

The goal of this clinical trial is to use a novel virtual reality intervention to test for efficacy in reducing alcohol use and increasing abstinence, with concomitant increases in future self-identification, future time perspective, and delay-of-reward, in early recovering alcohol use disorder (AUD) persons. The main question\[s\] this trial aims to answer are: Will the Virtual Reality (VR) intervention decrease the number of stimulant use days? Will the VR intervention produce longer abstinence periods during follow-up visits? Will the VR intervention increase alcohol abstinence rates? Will the VR intervention increase future self-identification? Will the VR intervention increase self-reported future time perspective? Will the VR intervention increase preference for delayed rewards in a laboratory delay discounting task on the study day? Will the VR intervention produce gains in the behavioral effects of future self-identification, future time perspective, and delayed rewards at the 30-day and 6-month follow-ups? Researchers will compare the experimental and control groups to see if there are differences in the results for the questions outlined above.

Interventions

  • Device Virtual Reality
    They will receive a Virtual Reality Park experience, which is an empty park with no avatars. They will then have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
  • Device Virtual Reality
    They will receive a Virtual Reality Park experience, which is an empty park with no avatars.

Primary outcome measures

  • Reduced Use of Drug Using Days [Time frame: Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit]
  • Increased Length of Abstinence [Time frame: Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.]
  • Increased (overall) Abstinence [Time frame: Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.]
  • Future Self-identification with Future Self Continuity Questionnaire [Time frame: Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit]
  • Future Time Perspective with the Delayed Discounting Behavioral Task and Future Self Continuity Questionnaire [Time frame: Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.]
  • Delayed Reward Preference with the Delayed Discounting Behavioral Task [Time frame: Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.]

Eligibility criteria

Inclusion criteria

  • Abstinence between ≥14 days and ≤1 year
  • Verbal endorsement of commitment to recovery
  • Outpatient
  • Psychotropic drugs for SUD-comorbidity
  • Drug/alcohol abstinence ≥ 24 hours at the time of the study day visit
  • English comprehension

Exclusion criteria

  • Unstable medical disorders
  • Habitual drug use
  • Mu-opioid drugs
  • Smell/taste disorders
  • Unstable psychiatric conditions
  • Extravagant/elaborate face tattoos

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Basic science

Study locations

United States · 1 center
  • Indiana University School of Medicine - Goodman Hal — Indianapolis

Identifiers

NCT: NCT06302413 · 1805574553; Aims 9-10 · 1R01AA029396-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗